[Contrast medica nephropathy. Better understanding of risk markers and follow up needed].
Sterner
Gunnar
G
Kliniken för njurmedicin och transplantation, Universitetssjukhuset, MAS, Malmö.
Hellström
Mikael
M
Lagerqvist
Bo
B
Aspelin
Peter
P
Nyman
Ulf
U
D015415:Biomarkers / Q000032:analysis; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D007456:Iodine Isotopes / Q000008:administration & dosage / Q000009:adverse effects; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control; D051437:Renal Insufficiency / Q000139:chemically induced / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors; D012449:Safety
D015415:Biomarkers; D003287:Contrast Media; D007456:Iodine Isotopes; D003404:Creatinine